Journal
ADVANCES IN CHRONIC KIDNEY DISEASE
Volume 25, Issue 3, Pages 281-290Publisher
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1053/j.ackd.2017.12.001
Keywords
Chronic kidney disease; Magnesium; Vascular calcification
Categories
Funding
- Amgen
- Bayer
- Sanofi-Genzyme
Ask authors/readers for more resources
Vascular calcification (VC) is associated with elevated cardiovascular mortality rates in patients with CKD. Recent clinical studies of patients with advanced CKD have observed an association between low serum magnesium (Mg) levels on one hand and elevated VC and cardiovascular mortality on the other. These findings have stimulated interest in understanding Mg's impact on CKD in general and the associated VC in particular. In vitro and preclinical in vivo data indicate that Mg has the potential to protect vascular smooth muscle cells against calcification via several different molecular mechanisms. Accordingly, data from pilot interventional studies in the clinic suggest that oral Mg supplementation reduces VC in patients with CKD. The present review provides an overview of our current understanding of the impact of Mg on the development of VC in patients with CKD. (C) 2017 by the National Kidney Foundation, Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available